Investigation of prognostic factors for second-line treatment with nivolumab for unresectable or recurrent esophageal cancer.

e16055Background: Nivolumab, an immune-checkpoint inhibitor for unresectable or recurrent esophageal cancer is used as second-line treatment. On the other hand, the relationship between indicators ...